Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Resilience and Vulnerability in Adolescents with Chronic Headache: a Population Study
Headache
P15 - Poster Session 15 (12:00 PM-1:00 PM)
7-005
To compare resilience resources (RR) and vulnerability risk (VR) in adolescents with chronic headache and non-headache controls, exploring the predictors of having the association of chronic headache and low RR and/or high VR.
Resilience is defined as a dynamic developmental process reflecting evidence of positive adaptation despite experiences of significant life adversity such as child maltreatment, parental divorce, poverty, chronic diseases, and chronic pain. The higher the RR the lower the VR.
Of 422 adolescents identified as the target sample, consents were obtained from 394 (93.4%), and analyzable data were provided by 339 (80.3%). Validated questionnaires were applied to the adolescents, their parents and teachers. Resilience resources and VR were assessed by the Sandra Prince-Embury Resilience Scale for Children and Adolescents. Odds ratio (OR) were obtained for categoric variables and robust ANOVA for continuing variables. Multivariate models estimated the predictors of low RR and high VR as a function of headache frequency.
The higher the frequency of headache, the lower the RR (F (3,335) = 3.74, p = 0.01) and the higher the VR (F (3,335) = 5.45, p < 0.01). Adolescents with high frequency headache (HFH, more than 10 headache attacks per month) showed a higher risk of low RR (OR = 7.0, CI 95% 1.7-28.0; p < 0.01) and a higher VR (OR = 18.0, CI 95% 2.1-146.0; p < 0,01). In the multivariate models, the association of chronic headache and low RR and/or high VR were independently predicted by male gender, pre-natal tobacco exposure, and the comorbidity with Attention Deficit Hyperactivity Disorder (p < 0.05).
Adolescents with HFH show lower resilience resources and higher vulnerability. These original findings have immediate clinical implications, since it reveals a novel and potential target in the treatment of these patients.
Authors/Disclosures
Renato Arruda, MD (Instituto Glia)
PRESENTER 		No disclosure on file
No disclosure on file
Marco A. Arruda, MD, PhD (Glia Institute) No disclosure on file